Baird lowered the firm’s price target on AdaptHealth (AHCO) to $14 from $16 and keeps an Outperform rating on the shares. The firm said the company is delivering in most categories, with strong BS/CF improvement, and overall operational improvement, except for Diabetes. The company’s diabetes business is bad, and it is getting a major overhaul.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AHCO: